Paradigm Biocapital Advisors LP Cytokinetics Inc Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 858,664 shares of CYTK stock, worth $26 Million. This represents 1.77% of its overall portfolio holdings.
Number of Shares
858,664Holding current value
$26 Million% of portfolio
1.77%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$444 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$359 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$301 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$242 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$184 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.85B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...